Bismuth subsalicylate: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
 
(5 intermediate revisions by one other user not shown)
Line 1: Line 1:
{{DrugProjectFormSinglePage
{{DrugProjectFormSinglePage
|authorTag={{RB}}
|OTC=Yes
|genericName=Bismuth subsalicylate
|aOrAn=a
|aOrAn=a
|drugClass=OTC [[antacid]]
|indicationType=treatment
|indicationType=treatment
|hasBlackBoxWarning=Yes
|indication=[[diarrhea]], [[heartburn]], [[indigestion]], [[nausea]], [[Abdominal pain|upset stomach]]
|adverseReactions=<!--Black Box Warning-->
|adverseReactions=darkening of the stool and/or tongue
 
 
 
<!--Black Box Warning-->
|blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
|blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
|blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>
|blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>


* Content
 


<!--Adult Indications and Dosage-->
<!--Adult Indications and Dosage-->


<!--FDA-Labeled Indications and Dosage (Adult)-->
<!--FDA-Labeled Indications and Dosage (Adult)-->
|fdaLIADAdult======Condition1=====
|fdaLIADAdult=====Indications====
 
* relieves:
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
* Dosing Information
 
:* Dosage
 
=====Condition3=====
 
* Dosing Information
 
:* Dosage
 
=====Condition4=====
 
* Dosing Information
 
:* Dosage
 
<!--Off-Label Use and Dosage (Adult)-->
 
<!--Guideline-Supported Use (Adult)-->
|offLabelAdultGuideSupport======Condition1=====
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information


:* Dosage
:* [[diarrhea]]
:* [[heartburn]]
:* [[indigestion]]
:* [[nausea]]
:* [[Abdominal pain|upset stomach]] associated with these symptoms


=====Condition2=====
====DIRECTIONS====
 
* chew or dissolve in mouth
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
* adults and children 12 years and over: 2 tablets every 1/2 to 1 hour as needed
* do not take more than 8 doses (16 tablets) in 24 hours
* children under 12 years: ask a doctor
* drink plenty of fluids to help prevent dehydration which may accompany [[diarrhea]].
* Other information: each tablet contains:
:* sodium less than 1 mg
:* salicylate 102 mg
:* calcium 140 mg
:* very low sodium
:* avoid excessive heat (over 104˚F or 40˚C)
* TAMPER EVIDENT: Do not use if individual compartments are torn or missing.
|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.


<!--Non–Guideline-Supported Use (Adult)-->
<!--Non–Guideline-Supported Use (Adult)-->
|offLabelAdultNoGuideSupport======Condition1=====
|offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.


<!--Pediatric Indications and Dosage-->
<!--Pediatric Indications and Dosage-->


<!--FDA-Labeled Indications and Dosage (Pediatric)-->
<!--FDA-Labeled Indications and Dosage (Pediatric)-->
|fdaLIADPed======Condition1=====
|fdaLIADPed=====Directions====
 
* children 12 years and over: 2 tablets every 1/2 to 1 hour as needed
* Dosing Information
|offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Off-Label Use and Dosage (Pediatric)-->
 
<!--Guideline-Supported Use (Pediatric)-->
|offLabelPedGuideSupport======Condition1=====
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.


<!--Non–Guideline-Supported Use (Pediatric)-->
<!--Non–Guideline-Supported Use (Pediatric)-->
|offLabelPedNoGuideSupport======Condition1=====
|offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.


<!--Contraindications-->
<!--Contraindications-->
|contraindications=* Condition1
|contraindications=<!--Warnings-->
 
|warnings======Reye's syndrome:=====
<!--Warnings-->
* Children and teenagers who have or are recovering from [[chicken pox]] or flu-like symptoms should not use this product. when using this product , if changes in behavior with [[nausea]] and [[vomiting]] occur, consult a doctor because these symptoms could be an early sign of [[Reye's syndrome]], a rare but serious illness.
|warnings=* Description
 
====Precautions====


* Description
=====Allergy alert:=====
* Contains [[salicylate]]. Do not take if you are
:* allergic to [[salicylates]] (including [[aspirin]])
:* taking other [[salicylate]] products
* Do not use if you have
:* bloody or [[black stools]]
:* an [[ulcer]]
:* a bleeding problem
* Ask a doctor before use if you have
:* fever
:* mucus in the stool
* Ask a doctor or pharmacist before use if you aretaking any drug for
:* [[anticoagulation]] (thinning of the blood)
:* [[diabetes]]
:* [[gout]]
:* [[arthritis]]
* When using this product
:* a temporary, but harmless darkening of the stool and/or tongue may occur.
* Stop use and ask a doctor if
:* symptoms get worse
:* ringing in the ears or loss of hearing occurs
:* [[diarrhea]] lasts more than 2 days
* If pregnant or breast-feeding, ask a health professional before use.
* Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center immediately.


<!--Adverse Reactions-->
<!--Adverse Reactions-->


<!--Clinical Trials Experience-->
<!--Clinical Trials Experience-->
|clinicalTrials=There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
|clinicalTrials=darkening of the stool and/or tongue
 
=====Body as a Whole=====
 
 
 
 
=====Cardiovascular=====
 
 
 
 
=====Digestive=====
 
 
 
 
=====Endocrine=====
 
 
 
 
=====Hematologic and Lymphatic=====
 
 
 
 
=====Metabolic and Nutritional=====
 
 
 
 
=====Musculoskeletal=====
 
 
 
 
=====Neurologic=====
 
 
 
 
=====Respiratory=====
 
 
 
 
=====Skin and Hypersensitivy Reactions=====
 
 
 
 
=====Special Senses=====
 
 
 
 
=====Urogenital=====
 
 
 
 
=====Miscellaneous=====
 
 
 
<!--Postmarketing Experience-->
|postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
|postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
=====Body as a Whole=====
=====Cardiovascular=====
=====Digestive=====
=====Endocrine=====
=====Hematologic and Lymphatic=====
=====Metabolic and Nutritional=====
=====Musculoskeletal=====
=====Neurologic=====
=====Respiratory=====
=====Skin and Hypersensitivy Reactions=====
=====Special Senses=====
=====Urogenital=====
=====Miscellaneous=====






<!--Drug Interactions-->
<!--Drug Interactions-->
|drugInteractions=* Drug
|drugInteractions=<!--Use in Specific Populations-->
:* Description
 
<!--Use in Specific Populations-->
|useInPregnancyFDA=* '''Pregnancy Category'''
|useInPregnancyFDA=* '''Pregnancy Category'''
|useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
|useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
Line 265: Line 114:
<!--Administration and Monitoring-->
<!--Administration and Monitoring-->
|administration=* Oral
|administration=* Oral
|monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.


* Intravenous
|monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.


* Description


<!--IV Compatibility-->
<!--IV Compatibility-->
Line 275: Line 122:


<!--Overdosage-->
<!--Overdosage-->
|overdose====Acute Overdose===
|overdose=There is limited information regarding <i>Overdose</i> of {{PAGENAME}} in the drug label.


====Signs and Symptoms====
<!--Pharmacology-->


* Description
<!--Drug box 2-->
|drugBox={{Drugbox2
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 476992845
| IUPAC_name = 2-Hydroxy-2''H'',4''H''-benzo[''d'']1,3-dioxa-2-bismacyclohexan-4-one
| image = Bismuth Wiki Str.png
| width = 200
| image2 = Bismuth Ball and stick.png


====Management====
| tradename = [[Pepto-Bismol]]
| Drugs.com = {{Drugs.com|MTM|bismuth-subsalicylate}}
| MedlinePlus = a607040
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US =  
| pregnancy_category =
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--            / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL        / P      / POM / CD / Class A, B, C -->
| legal_US = OTC
| legal_status = 
| routes_of_administration = Oral


* Description
<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion =


===Chronic Overdose===
<!--Identifiers-->
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 14882-18-9
| ATC_prefix = none
| ATC_suffix =
| PubChem = 16682734
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01294
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 17215772
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 62TEY51RR1
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = D00728
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 261649
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1120


There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
<!--Chemical data-->
| chemical_formula = 
| C=7 | H=5 | Bi=1 | O=4
| molecular_weight = 362.093 g/mol
| smiles = O[Bi]1OC(=O)c2ccccc2O1
| InChI = 1/C7H6O3.Bi.H2O/c8-6-4-2-1-3-5(6)7(9)10;;/h1-4,8H,(H,9,10);;1H2/q;+3;/p-3/rC7H5BiO4/c9-7-5-3-1-2-4-6(5)11-8(10)12-7/h1-4,10H
| InChIKey = ZREIPSZUJIFJNP-PEVRGXKGAC
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C7H6O3.Bi.H2O/c8-6-4-2-1-3-5(6)7(9)10;;/h1-4,8H,(H,9,10);;1H2/q;+3;/p-3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = ZREIPSZUJIFJNP-UHFFFAOYSA-K
}}


<!--Pharmacology-->


<!--Drug box 2-->
<!--Mechanism of Action-->
|drugBox=<!--Mechanism of Action-->
|mechAction=<!--Structure-->
|mechAction=*  
|structure=====ACTIVE INGREDIENT (IN EACH TABLET)=====
* Bismuth subsalicylate 262 mg
 
* (total salicylate 102 mg per tablet)
 
=====INACTIVE INGREDIENTS=====
* calcium carbonate, D and C red 27 aluminum lake, flavor, magnesium stearate, mannitol, pregelatinized starch, saccharin sodium.


<!--Structure-->
|structure=*


: [[File:{{PAGENAME}}01.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]


<!--Pharmacodynamics-->
<!--Pharmacodynamics-->
Line 313: Line 215:


<!--How Supplied-->
<!--How Supplied-->
|howSupplied=*
|howSupplied=
|packLabel=<!--Patient Counseling Information-->
|storage=* avoid excessive heat (over 104˚F or 40˚C)
|packLabel=====PRINCIPAL DISPLAY PANEL====
: [[File:Bismuth PDP.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
 
====Ingredients and Appearance====
 
: [[File:Bismuth Ing and App.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
 
<!--Patient Counseling Information-->
|fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.
|fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.


Line 321: Line 231:


<!--Brand Names-->
<!--Brand Names-->
|brandNames=* ®<ref>{{Cite web | title = | url = }}</ref>
|brandNames=* BISMATROL®<ref>{{Cite web | title = Bismuth subsalicylate | url = http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e5021687-11aa-472a-bd06-151415e1e2b3}}</ref>


<!--Look-Alike Drug Names-->
<!--Look-Alike Drug Names-->
|lookAlike=* A® — B®<ref name="www.ismp.org">{{Cite web  | last =  | first =  | title = http://www.ismp.org | url = http://www.ismp.org | publisher =  | date =  }}</ref>
<!--Drug Shortage Status-->
|drugShortage=
|drugShortage=
}}
}}
{{PillImage
{{PillImage|fileName=Pink_Bismuth_NDC_06030235.jpg|drugName=Pink Bismuth|NDC=06030235|drugAuthor=Qualitest Pharmaceuticals|ingredients=BISMUTH SUBSALICYLATE[BISMUTH CATION]|pillImprint=RH046|dosageValue=262|dosageUnit=mg|pillColor=Pink|pillShape=Round|pillSize=15|pillScore=1}}
|fileName=No image.jpg
}}
{{LabelImage
|fileName={{PAGENAME}}11.png
}}
{{LabelImage
|fileName={{PAGENAME}}11.png
}}
<!--Pill Image-->
 
 
 
<!--Label Display Image-->
 
 
 




Latest revision as of 15:30, 8 August 2015

Bismuth subsalicylate
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rabin Bista, M.B.B.S. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
NOTE: Most over the counter (OTC) are not reviewed and approved by the FDA. However, they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies.

Overview

Bismuth subsalicylate is a OTC antacid that is FDA approved for the treatment of diarrhea, heartburn, indigestion, nausea, upset stomach. Common adverse reactions include darkening of the stool and/or tongue.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Indications

  • relieves:

DIRECTIONS

  • chew or dissolve in mouth
  • adults and children 12 years and over: 2 tablets every 1/2 to 1 hour as needed
  • do not take more than 8 doses (16 tablets) in 24 hours
  • children under 12 years: ask a doctor
  • drink plenty of fluids to help prevent dehydration which may accompany diarrhea.
  • Other information: each tablet contains:
  • sodium less than 1 mg
  • salicylate 102 mg
  • calcium 140 mg
  • very low sodium
  • avoid excessive heat (over 104˚F or 40˚C)
  • TAMPER EVIDENT: Do not use if individual compartments are torn or missing.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Bismuth subsalicylate in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Bismuth subsalicylate in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Directions

  • children 12 years and over: 2 tablets every 1/2 to 1 hour as needed

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Bismuth subsalicylate in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Bismuth subsalicylate in pediatric patients.

Contraindications

There is limited information regarding Bismuth subsalicylate Contraindications in the drug label.

Warnings

Reye's syndrome:
  • Children and teenagers who have or are recovering from chicken pox or flu-like symptoms should not use this product. when using this product , if changes in behavior with nausea and vomiting occur, consult a doctor because these symptoms could be an early sign of Reye's syndrome, a rare but serious illness.
Allergy alert:
  • Do not use if you have
  • Ask a doctor before use if you have
  • fever
  • mucus in the stool
  • Ask a doctor or pharmacist before use if you aretaking any drug for
  • When using this product
  • a temporary, but harmless darkening of the stool and/or tongue may occur.
  • Stop use and ask a doctor if
  • symptoms get worse
  • ringing in the ears or loss of hearing occurs
  • diarrhea lasts more than 2 days
  • If pregnant or breast-feeding, ask a health professional before use.
  • Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center immediately.

Adverse Reactions

Clinical Trials Experience

darkening of the stool and/or tongue

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Bismuth subsalicylate in the drug label.

Drug Interactions

There is limited information regarding Bismuth subsalicylate Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

  • Pregnancy Category


Pregnancy Category (AUS):

  • Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Bismuth subsalicylate in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Bismuth subsalicylate during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Bismuth subsalicylate with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Bismuth subsalicylate with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Bismuth subsalicylate with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Bismuth subsalicylate with respect to specific gender populations.

Race

There is no FDA guidance on the use of Bismuth subsalicylate with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Bismuth subsalicylate in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Bismuth subsalicylate in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Bismuth subsalicylate in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Bismuth subsalicylate in patients who are immunocompromised.

Administration and Monitoring

Administration

  • Oral

Monitoring

There is limited information regarding Monitoring of Bismuth subsalicylate in the drug label.

IV Compatibility

There is limited information regarding IV Compatibility of Bismuth subsalicylate in the drug label.

Overdosage

There is limited information regarding Overdose of Bismuth subsalicylate in the drug label.

Pharmacology

Template:Px
Template:Px
Bismuth subsalicylate
Systematic (IUPAC) name
2-Hydroxy-2H,4H-benzo[d]1,3-dioxa-2-bismacyclohexan-4-one
Identifiers
CAS number 14882-18-9
ATC code none
PubChem 16682734
DrugBank DB01294
Chemical data
Formula Template:OrganicBox atomTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox 
Mol. mass 362.093 g/mol
SMILES eMolecules & PubChem
Pharmacokinetic data
Bioavailability ?
Metabolism ?
Half life ?
Excretion ?
Therapeutic considerations
Pregnancy cat.

?

Legal status

OTC(US)

Routes Oral

Mechanism of Action

There is limited information regarding Bismuth subsalicylate Mechanism of Action in the drug label.

Structure

ACTIVE INGREDIENT (IN EACH TABLET)=

  • Bismuth subsalicylate 262 mg
  • (total salicylate 102 mg per tablet)
INACTIVE INGREDIENTS
  • calcium carbonate, D and C red 27 aluminum lake, flavor, magnesium stearate, mannitol, pregelatinized starch, saccharin sodium.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Bismuth subsalicylate in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Bismuth subsalicylate in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Bismuth subsalicylate in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Bismuth subsalicylate in the drug label.

How Supplied

There is limited information regarding Bismuth subsalicylate How Supplied in the drug label.

Storage

  • avoid excessive heat (over 104˚F or 40˚C)

Images

Drug Images

{{#ask: Page Name::Bismuth subsalicylate |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

PRINCIPAL DISPLAY PANEL

This image is provided by the National Library of Medicine.

Ingredients and Appearance

This image is provided by the National Library of Medicine.

{{#ask: Label Page::Bismuth subsalicylate |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Bismuth subsalicylate in the drug label.

Precautions with Alcohol

  • Alcohol-Bismuth subsalicylate interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

Look-Alike Drug Names

There is limited information regarding Bismuth subsalicylate Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

  1. ↑ "Bismuth subsalicylate".

{{#subobject: 

 |Page Name=Bismuth subsalicylate
 |Pill Name=Pink_Bismuth_NDC_06030235.jpg
 |Drug Name=Pink Bismuth
 |Pill Ingred=BISMUTH SUBSALICYLATE[BISMUTH CATION]|+sep=;
 |Pill Imprint=RH046
 |Pill Dosage=262 mg
 |Pill Color=Pink|+sep=;
 |Pill Shape=Round
 |Pill Size (mm)=15
 |Pill Scoring=1
 |Pill Image=
 |Drug Author=Qualitest Pharmaceuticals
 |NDC=06030235

}}

Retrieved from "https://www.wikidoc.org/index.php?title=Bismuth_subsalicylate&oldid=1128518"